Overall, the present real‐world study supports previous evidence from an RCT and a real‐world study with a matched controlled group that the digital device ESYSTA is associated with significant and continuous reductions in HbA1c levels in T1D and T2D insulin‐treated people with diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.